An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Overview

This article describes a high-throughput drug sensitivity assay designed for primary multiple myeloma cells. The method involves reconstructing the bone marrow microenvironment and allows for non-invasive longitudinal quantification of cell viability.

Key Study Components

Area of Science

• Neuroscience
• Oncology
• Cell Biology

Background

• Multiple myeloma is a type of blood cancer affecting plasma cells.
• Assessing drug sensitivity is crucial for effective treatment.
• Traditional assays often require cell separation, limiting their utility.
• This study aims to improve the assessment of drug responses in a more physiologically relevant environment.

Purpose of Study

• To quantify the chemo sensitivity of multiple myeloma primary cells.
• To evaluate the effectiveness of various chemotherapeutic agents.
• To enable longitudinal monitoring of cell viability without disrupting the microenvironment.

Methods Used

• Isolation of multiple myeloma cells from fresh bone marrow aspirate.
• Mixing cells with patient-derived stroma and collagen.
• Seeding the cell mixture onto multi-well plates.
• Sequential imaging of cells over a 96-hour incubation period using a motorized stage microscope.

Main Results

• Viability curves for each drug and concentration were generated.
• The method allows testing multiple agents against a single patient specimen.
• Longitudinal measurements of cell viability were successfully obtained.
• The technique demonstrates advantages over traditional endpoint assays.

Conclusions

• This high-throughput assay provides a more accurate assessment of drug sensitivity.
• It preserves the bone marrow microenvironment, enhancing relevance to patient conditions.
• The method can facilitate personalized treatment strategies for multiple myeloma.

Frequently Asked Questions